首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Self-assembling peptide for co-delivery of HIV-1 CD8+T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response
【24h】

Self-assembling peptide for co-delivery of HIV-1 CD8+T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response

机译:自组装肽,可共同递送HIV-1 CD8 + T细胞表位和Toll样受体7/8激动剂R848,以诱导单核细胞衍生的树突状细胞成熟并增强多功能细胞毒性T淋巴细胞(CTL)反应

获取原文
获取原文并翻译 | 示例
           

摘要

Peptide based vaccine that incorporates one or several highly conserved CD8+ T cells epitopes to induce potent cytotoxic T lymphocyte (CTL) response is desirable for some infectious diseases, such as HIV-1 (human immunodeficiency virus-1), and cancers. However, the CD8+ T cells epitope is often weakly immunogenic, and thus requires a specific adjuvant or delivery system to enhance the efficiency. Here we investigated the use of self-assembling peptide EAK16-II based platform to achieve the co-delivery of CD8+ T cells epitope and TLR7/8 agonists (R848 or R837) for augmenting DCs maturation and HIV-1 specific CTL response. HIV-1 CTL epitope SL9 was conjugated with EAK16-II to obtain SL9-EAK16-II, which further spontaneously co-assembled with R848 or R837 in aqueous solution, forming co-assembled nanofibers. Fluorescence spectra and calorimetrical titration revealed the interaction between SL9-EAK16-II assemblies and R848 or R837 via hydrogen bonding and hydrophobic interaction, with the binding affinity (dissociation constant K-d) of 0.62 mu M or 0.53 mu M, respectively. Ex vivo generated DCs from HIV-1+ patients pulsed with the SL9-EAK16-II/R848 nanofibers stimulated significantly more polyfunctional SL9 specific CTLs, compared to the DCs pulsed with SL9 alone or the mixture of SL9 and TLR agonist. Furthermore, the nanofibers elicited stronger SL9 specific CTL response in vaccinated mice. Our findings suggest the self-assembling peptide EAK16-II might be used as a new delivery system for peptide based vaccines. (C) 2016 Elsevier B.V. All rights reserved.
机译:掺入一种或几种高度保守的CD8 + T细胞表位以诱导有效的细胞毒性T淋巴细胞(CTL)反应的基于肽的疫苗,对于某些传染性疾病(例如HIV-1(人类免疫缺陷病毒-1))和癌症是理想的。但是,CD8 + T细胞表位通常是弱免疫原性的,因此需要特定的佐剂或递送系统来提高效率。在这里,我们研究了基于自组装肽EAK16-II的平台的使用,以实现CD8 + T细胞表位和TLR7 / 8激动剂(R848或R837)的共递送,以增强DC的成熟度和HIV-1特异性CTL反应。将HIV-1 CTL表位SL9与EAK16-II缀合以获得SL9-EAK16-II,其进一步在水溶液中与R848或R837自发共组装,形成共组装的纳米纤维。荧光光谱和量热滴定表明,SL9-EAK16-II组装体与R848或R837之间通过氢键和疏水相互作用相互作用,结合亲和力(解离常数K-d)分别为0.62μM或0.53μM。与单独用SL9或SL9和TLR激动剂的混合物刺激的DC相比,用SL9-EAK16-II / R848纳米纤维脉冲的HIV-1 +患者的离体产生的DC刺激了更多的多功能SL9特异性CTL。此外,纳米纤维在接种疫苗的小鼠中引起更强的SL9特异性CTL反应。我们的发现表明,自组装肽EAK16-II可用作基于肽的疫苗的新递送系统。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号